Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam Tosilate for ICU Sedation
NCT05152303Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of remimazolam in sedation, sponsored by Fujian Shengdi Pharmaceuticals. Started Oct 2022; status: completed.
02
Drugs
remimazolam
03
Conditions
sedation
Beyond the preview
Go deeper on NCT05152303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152303.